SCHEMBL3246426

SCHEMBL3246426

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(NS(=O)(=O)c4cccc(F)c4)cc3c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TP53 P04637 3/20 0.44
MAPT P10636 3/20 0.44
LMNA P02545 2/20 0.44
THRB P10828 1/20 0.44
PKM P14618 1/20 0.44
HIF1A Q16665 5/20 0.43
POLB P06746 1/20 0.43
JAK2 O60674 1/20 0.43
JAK3 P52333 1/20 0.43
ITK Q08881 1/20 0.42
BRD4 O60885 3/20 0.42
BACE1 P56817 1/20 0.41
ADRB3 P13945 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3246250 0.92 HIF1A (0.53) MEN1KMT2AALDH1A1HPGDALOX15
SCHEMBL3251191 0.91 PKM (0.49) MEN1KMT2AALDH1A1HPGDALOX15
SCHEMBL3255461 0.91 BRD4 (0.52) MEN1KMT2AALDH1A1HPGDALOX15
SCHEMBL3247456 0.90 BRD4 (0.55) MEN1KMT2AALDH1A1HPGDALOX15
SCHEMBL3247530 0.89 HSD17B10 (0.48) MEN1KMT2AALDH1A1HPGDALOX15
SCHEMBL3244722 0.89 PKM (0.56) MEN1KMT2AALDH1A1HPGDALOX15
SCHEMBL3252388 0.87 HSD17B10 (0.47) MEN1KMT2AALDH1A1HPGDALOX15
SCHEMBL3248967 0.87 PKM (0.47) MEN1KMT2AALDH1A1HPGDALOX15
SCHEMBL3249004 0.87 HIF1A (0.51) MEN1KMT2AALDH1A1HPGDALOX15
SCHEMBL3254501 0.87 ITK (0.41) MEN1KMT2AALDH1A1HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 MEN1 3749/4885KMT2A 1882/4885ALDH1A1 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.